ZyVersa Therapeutics Inc (ZVSA) News

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause...

Form 8-K - Current report

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

WESTON, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a...

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

Heart failure with preserved ejection fraction (HFpEF), a chronic inflammatory condition, is a leading cause of...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form DEF 14A - Other definitive proxy statements

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form PRE 14A - Other preliminary proxy statements

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies...

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with...

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Form 8-K - Current report

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with...